Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

1 GENE THERAPY TRIAL FOR CHOROIDEREMIA

AN OPEN LABEL DOSE ESCALATION PHASE 1 CLINICAL TRIAL OF RETINAL GENE THERAPY FOR CHOROIDEREMIA USING AN ADENO-ASSOCIATED VIRAL VECTOR (AAV2) ENCODING RAB-ESCORT PROTEIN 1 (REP1)

Patients with a genetic diagnosis of choroideremia will undergo gene therapy using two doses of adeno-associated viral (AAV) vector encoding the CHM gene. The vector will be administered to the subretinal space by injection during vitrectomy surgery. Patients will be followed up for 2 years to assess safety and efficacy.

Find out more from BBC News (2011)

More about the first results on BBC News (2014)

Read a press release about the first results (16 January 2014).

  • Chief Investigator: RE MacLaren
  • Principal Investigators: MC Seabra, T Tolmachova, L Seymour, AR Webster, SM Downes, AJ Lotery, GCM Black
  • Sponsor: University of Oxford
  • Phase I/II clinical trial
  • Study duration: Sep 2011 - Oct 2015
  • Recruitment: Ongoing
  • Ethics Approval: GTAC171
  • EudraCT number: 2009-014617-27

2 SUBRETINAL IMPLANTS

THE SAFETY AND EFFECTIVENESS OF SUBRETINAL IMPLANTS FOR THE PARTIAL RESTORATION OF THE EYESIGHT OF BLIND PATIENTS: A PROSPECTIVE MONO- AND MULTICENTRIC TRIAL ON THE BASIS OF A COMPARISON OF THE FUNCTION BETWEEN AN ACTIVATED AND DEACTIVATED IMPLANT FOR PATIENTS WITH DEGENERATIVE RETINAL DISEASES.

This study will assess the role of the electronic retinal implant in restoring vision to patients who are blind from retinitis pigmentosa. Six patients have currently undergone surgery with the device and will be followed up for one year. The aim of the study is to assess the long-term practicalities of having an electronic retina and is part of a European multicenter study in collaboration with Retina Implant AG, the manufacturer of the device.

Find out  more from BBC News.

  • Chief Investigator: RE MacLaren
  • Principal Investigators: SM Downes, M Groppe
  • Sponsor: Retinal Implant AG
  • Study Duration: Mar 2012 - Dec 2013
  • Recruitment: closed (6)
  • Ethics Approval: 10/H0808/40

3 EFFECT OF OCULAR DISEASES ON SLEEP AND ‘BODY-CLOCKS’ (CIRCADIAN RHYTHMS)

A QUESTIONNAIRE BASED STUDY LOOKING AT THE EFFECTS OF PATIENTS WITH VARIOUS EYE CONDITIONS AND THEIR SLEEP/WAKE PATTERN. WE ARE LOOKING TO RECRUIT APPROXIMATELY 3000 PARTICIPANTS OVER THE WHOLE OF THE THAMES VALLEY IN NEXT 5 YEARS.

  • Chief Investigator: RG Foster
  • Principal Investigators: SM Downes
  • Study Start: Jun 2011 – May 2016
  • Sponsor: University of Oxford
  • Recruitment: Ongoing (3000 total)
  • Ethics Approval: 11/SC/0093

4 RETINITIS PIGMENTOSA

TRANSCORNEAL ELECTRICAL STIMULATION FOR THE TREATMENT OF RETINITIS PIGMENTOSA – A MULTICENTRE SAFETY STUDY OF THE OKUSTIM SYSTEM (TESOLA STUDY)

The aim of the study is to determine whether prolonged use of electrical stimulation delivered by the Okustim device shows improvement in vision in patients with retinitis pigmentosa.

  • Chief Investigator: RE MacLaren
  • Principal Investigators: AR Webster, SM Downes, M Groppe, J Jolly, S Wagner
  • Sponsor: University of Oxford
  • Study Duration: Apr 2013 – Mar 2015
  • Ethics Approval: 12/SW/0293

5 OZURDEX VERSUS LUCENTIS (COMO STUDY)

A 12 MONTH, MULTICENTRE, RANDOMISED, PARALLEL GROUP STUDY TO COMPARE THE EFFICACY AND SAFETY OF OZURDEX VERSUS LUCENTIS IN PATIENTS WITH BRANCH RETINAL VEIN OCCLUSION

COMO is a research study of a drug called Ozurdex. This drug is licensed for treatment of patients with macular oedema (swelling of part of the eye) due to Branch Retinal Vein Occlusion (BRVO). Lucentis is another drug which is also licensed for the treatment of retinal vein occlusion (BRVO or central retinal vein occlusion – CRVO, as well as more commonly Wet Age Related Macular Degeneration) Although both drugs are licensed for the treatment of BRVO it is not known if one is better than the other at treating macular oedema. The study is intended to compare the efficacy and safety of Ozurdex versus Lucentis in patients with BRVO.

  • Principal Investigator: NV Chong
  • Study Duration: Apr 2012 – Mar 2014
  • Sponsor: Allergan Pharmaceuticals
  • Recruitment: Ongoing
  • Ethics Approval:11/LO/1023
  • EudraCT number: 2010-023900-29

6 CLINICAL AND GENETIC ANALYSIS OF INHERITED RETINAL DEGENERATIONS

This study aims to characterise the specific clinical features in patients with inherited retinal degeneration and to identify the specific genetic changes which have caused the disease

  • Principal Investigator: Susan Downes
  • Study Duration: Feb 2009 - Jan 2015
  • Sponsor: University of Oxford
  • Recruitment: ongoing
  • Ethics Approval: 08/H0302/96

7 BINOCULAR VISION IN MONOCULAR PSEUDOPHAKIA

The natural lens in the eye is able to adjust its shape to focus at different distances. This process is known as accommodation and is active until approximately 50 years of age.  Following cataract surgery, the lens that is taken out of the eye is replaced by an intraocular lens (IOL). Traditionally IOLs only have one focal point designed so focus cannot be adjusted for different distances. A new style of IOL was developed in 2009 in an attempt to artificially provide clear vision at different distances. This study will investigate the difference in vision and depth perception with the new multifocal lens comparing it with the traditional monofocal lens by means of non-invasive vision tests and questionnaires.

  • Chief Investigator: RE MacLaren
  • Co-Principal Investigators: CK Patel, PH Rosen, J Jolly
  • Sponsor: Oxford University Hospitals NHS Trust
  • Study Start: Apr 2013 Mar 2015
  • Ethics Approval: 12/SC/0575
  • Sponsor: University of Oxford
  • More information

8 A STUDY OF THE ABILITY OF POORLY SIGHTED PATIENTS TO DETECT LIGHT AND COLOUR IN A SMALL VISUAL DISPLAY

Dr Stephen Hicks has developed a new type of electronic visual aid that may be able to help improve the independence of people with severely impaired vision. The visual aid will be worn like a pair of spectacles with tiny lights built into lenses in order to help patients who are losing sight from retinitis pigmentosa to see nearby objects.

  • Chief Investigator: S Hicks
  • Principal Investigators: SM Downes
  • Sponsor: University of Oxford
  • Study Duration: Jan 2013 – Dec 2016
  • Recruitment: Ongoing (60 total)
  • Ethics Approval: 11/SC/0186

9 CHRONIC CENTRAL SERIOUS CHORIORETINOPATHY

PROSPECTIVE RANDOMIZED CONTROLLED TREATMENT TRIAL FOR CHRONIC CENTRAL SEROUS CHORIORETINOPATHY (PLACE STUDY)

Chronic central serous chorioretinopathy (CSR) is a relatively frequent eye disease that often occurs in patients in the professionally active age range. In this disease, there is pooling of fluid under the central retina (the macula). The proposed study will compare the effects of macular micropulse laser to photodynamic therapy (PDT) as treatments for CSR in a prospective randomized controlled trial. Other trial sites include

  • Chief Investigator: CJF Boon
  • Principal Investigators: SM Downes, RE MacLaren, NV Chong
  • Sponsor: Radboud University Nijmegen Medical Centre,
  • Study Duration: Jan 2013 – Dec 2016
  • Recruitment: Not yet started
  • Ethics Approval: 

10 THE AMILORIDE CLINICAL TRIAL IN OPTIC NEURITIS (ACTION)

ACTION is a Phase II study for patients diagnosed with Optic Neuritis. It is led by Dr. Matt Craner and Justin McKee in the Neurology department. It will be looking at treating patients with a drug called Amiloride. 

The aim of this study is to investigate the effect of Amiloride as a new therapy for protecting nerves from damage following inflammation.

  • Chief Investigator: Matthew Craner
  • Principal Investigator: Justin McKee
  • Study start: March 2013
  • Ethics Approval: 13/SC/022
  • Sponsor: MS Society 

11 VISUAL AND FUNCTIONAL ASSESSMENT IN LOW VISION PATIENTS

  • Chief Investigator: Prof Robert MacLaren
  • Co-Principal Investigator: Jasleen K Jolly
  • Study Start Date: June 2013
  • Ethics Approval: 13/SC/0234
  • Sponsor: University of Oxford
  • More information